<sup>99m</sup>Tc-DTPA orbital SPECT/CT in thyroid-associated ophthalmopathy: current evidence and emerging applications.
Authors
Affiliations (2)
Affiliations (2)
- Baoding No.1 Central Hospital, Baoding, 071000, Hebei, China.
- Baoding No.1 Central Hospital, Baoding, 071000, Hebei, China. [email protected].
Abstract
Thyroid-associated ophthalmopathy (TAO), an autoimmune inflammatory disease of the orbit, requires objective assessment of disease activity and severity to guide management. The Clinical Activity Score (CAS) is widely used for this purpose, but its reliability is limited by subjectivity and interobserver variability, and conventional structural imaging cannot reliably distinguish early inflammation from fibrotic remodeling. Orbital single-photon emission computed tomography/computed tomography (SPECT/CT) using 99mTc-DTPA-a small hydrophilic tracer that extravasates in proportion to inflammation-induced microvascular permeability-provides a noninvasive means of visualizing and quantifying orbital inflammatory activity. This review summarizes the imaging principles and quantitative methods of orbital SPECT/CT, from semi-quantitative uptake ratios to corrected SUVmax-based absolute quantification and multiparametric models, and critically appraises the evidence for its clinical applications in TAO activity stratification, prediction of glucocorticoid response, and longitudinal treatment monitoring. Emerging applications, including SPECT/CT radiomics with external validation and artificial intelligence-based image analysis, are also discussed. Throughout, established evidence is distinguished from exploratory applications that require prospective validation, providing a balanced basis for the further evaluation and potential clinical incorporation of orbital SPECT/CT in individualized TAO management.